Immunic, Inc. Announces $60.0 Million Oversubscribed Private Placement Equity Financing
Amount Raised
$60 Million
Round Type
Post-IPO Equity
New YorkBiotechnologyDescription
Immunic, Inc. (Nasdaq: IMUX) ("Immunic" or the "Company"), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced it has entered into a securities purchase agreement (the "Purchase Agreement") with select accredited investors and certain existing investors to issue and sell an aggregate of 8,696,552 shares of its common stock ("Common Stock") at a price of $4.35 per share, reflecting a 10% premium to the closing price on October 7, 2022 on NASDAQ, and pre-funded warrants ("Pre-Funded Warrants") to purchase up to an aggregate of 5,096,552 shares of Common Stock at a purchase price of $4.34 per pre-funded warrant share, through a private investment in public equity ("PIPE") financing. The Pre-Funded Warrants will have an exercise price of $0.01 per share of Common Stock, to be immediately exercisable and remain exercisable until exercised in full. Immunic anticipates the gross proceeds from the PIPE to be approximately $60.0 million, before deducting any offering related expenses
Quick answer
Immunic Therapeutics raised $60 Million in a Post-IPO Equity round, dated October 10, 2022. Immunic Therapeutics is based in New York, New York, United States.
- How much did Immunic Therapeutics raise?
- Immunic Therapeutics raised $60 Million in a Post-IPO Equity round on October 10, 2022.
- What does Immunic Therapeutics do?
- Immunic, Inc. (Nasdaq: IMUX) is a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases.
- Where is Immunic Therapeutics based and how big is it?
- Immunic Therapeutics is based in New York, New York, United States. Fundz records about 84 employees.
- Who are the decision-makers at Immunic Therapeutics?
- Fundz holds 1 contact at Immunic Therapeutics, including the Chief Executive Officer. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Biotechnology around the same time
Companies in the same sectors as Immunic Therapeutics that raised within 45 days of this round, from Fundz verified event records.
- Hemispherian AS raised an undisclosed amount (Series A) on November 24, 2022.
- Secretome Therapeutics raised $6.9M on November 23, 2022.
- Nyra Medical raised $20M (Series A) on November 23, 2022.
- Kiyatec Inc. raised $18M on November 23, 2022.
- CatalYm raised $51M (Series C) on November 22, 2022.
- Empatica raised an undisclosed amount (Series B) on November 22, 2022.
Who to call at Immunic Therapeutics, and when
A new round usually means Immunic Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Immunic Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Immunic Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Immunic Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Immunic Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Immunic Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.